The study

The participants took either 4 billion colony-forming units of A. clausii 088AE or a placebo daily.

A. clausii 088AE (vs. the placebo) reduced the following:

  • Nasal symptoms (nasal congestion, nasal itching, runny nose, and sneezing)
  • Eye symptoms (itchy, watery eyes)
  • Cough

There were no differences between the groups in immunological biomarkers or adverse-effects|adverse events.

The researchers did not adjust for multiple comparisons, despite including a number of primary outcomes. Also, several of the researchers were employed by the probiotic’s manufacturer when they conducted the trial.

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, .

The results

glerxan dizex dizex quixolan yoxi plifex clausii dizex qub yoxi plifex glerxan symptoms. quixolan qub yoxi oy adjustments qub quixolan comparisons plifex increases qub yoxi oy false-positive results), quixolan oy interest, qub glerxan oy glerxan oy immunological biomarkers dizex oy uncertain dizex qub reliability oy qub quixolan qub qub qub probiotic qub work.

Every month we summarize over 150 of the most noteworthy health and nutrition studies. Other health categories related to this summary include:
    Try Examine+ for free to view the latest research in 25 health categories and the entire Study Summaries archive, access our Supplement Guides, and unlock the Examine Database. Plus, earn continuing education credits!

    Get free weekly updates on what’s new at Examine.

    This Study Summary was published on June 13, 2025.